Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125744341 | 12574434 | 1 | I | 20160621 | 0 | 20160719 | 20160719 | DIR | 65.00 | YR | F | N | 0.00000 | 20160718 | N | PH | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125744341 | 12574434 | 1 | PS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 1 TAB DAILY PO | D | D | F0033 | 20180930 | 0 | 1 | DF | COATED TABLET | QD | ||
| 125744341 | 12574434 | 3 | C | LEVOXYL | LEVOTHYROXINE SODIUM | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 4 | C | METOPROLO TAR | 2 | 0 | |||||||||||||
| 125744341 | 12574434 | 6 | C | ZOLPIDEM | ZOLPIDEMOLPIDEM TARTRATE | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 8 | C | KLOR-CON | POTASSIUM CHLORIDE | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 10 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 12 | C | WARFARIN | WARFARIN | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 14 | C | SIMVASTATIN. | SIMVASTATIN | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 16 | C | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 18 | C | COREG | CARVEDILOL | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 20 | C | AMBIEN | ZOLPIDEM TARTRATE | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 22 | C | ASPIRIN. | ASPIRIN | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 24 | C | FOSINOPRIL | FOSINOPRIL | 1 | 0 | ||||||||||||
| 125744341 | 12574434 | 26 | C | FLUTICASEON | 2 | 0 | |||||||||||||
| 125744341 | 12574434 | 28 | C | DILTIAZEM. | DILTIAZEM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125744341 | 12574434 | 1 | Neoplasm malignant |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125744341 | 12574434 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125744341 | 12574434 | Cardiac disorder | |
| 125744341 | 12574434 | Diarrhoea | |
| 125744341 | 12574434 | Fluid retention | |
| 125744341 | 12574434 | Hair disorder | |
| 125744341 | 12574434 | Insomnia | |
| 125744341 | 12574434 | Nausea | |
| 125744341 | 12574434 | Premature ageing | |
| 125744341 | 12574434 | Skin disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| Event ID | CASEID | RPSR COD |
|---|---|---|
| 125744341 | 12574434 | HP |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125744341 | 12574434 | 1 | 201306 | 0 |